PharmaShots

MAY 24, 2023

Alvotech will be responsible for the development and commercial supply Advanz Pharma will leverage its existing specialty and hospital capabilities in the EU to ensure successful market registration, commercialization, and patient access. Your go-to media platform for customized news ranging for multiple indications.

Biosimilars 40

Biosimilars Hospitals 40

STAT

DECEMBER 5, 2022

… Johnson & Johnson said it does not intend to make an offer for Horizon Therapeutics, days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company , Bloomberg News writes. regulatory approval, Bloomberg News says. Food and Drug Administration.

130

130

PharmaShots

MAY 10, 2023

Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Biosimilars 40

Biosimilars 40

Pharmaceutical Technology

MAY 26, 2023

The European Medicines Agency (EMA) has accepted two marketing authorisation applications (MAA) from Sandoz for the proposed biosimilar denosumab. If approved, this has the potential to provide people living with osteoporosis and cancer of the bone or bone metastasis access to a cost-effective and high-quality treatment option.

Biosimilars 52

Biosimilars Packaging 52

pharmaphorum

AUGUST 21, 2020

New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week.

Vaccines 104

Vaccines 104

PharmaShots

APRIL 4, 2023

Shots: The EC has granted marketing authorization for Hyrimoz (adalimumab-adaz) high-concentration formulation, a biosimilar to Humira (adalimumab) in the EU. Hyrimoz has been approved for use in all the indications covered by the reference Humira, incl.

Biosimilars 49

Biosimilars 49

Fuld & Company Blog

APRIL 5, 2024

To overcome these challenges and foster growth, boutique investment banks need access to platforms and solutions that directly address their core pain points. Difficulty in differentiating amidst market competition. Strategies to achieve this include: Regular publication of market updates and thought leadership.

Packaging 52

Packaging 52

PharmaShots

APRIL 26, 2023

Spectrum’s combined assets & commercial infrastructure will accelerate Rolvedon’s launch for patients' benefit & drive further growth The combination of Assertio’s Omni-Channel digital sales capabilities & Rolvedon's in-person commercial team will enhance market access & growth across all products Ref: Globenewswire (..)

56

56

PharmaShots

APRIL 11, 2023

Shots: The company received marketing authorization from Health Canada for expanded use of Orkambi to treat cystic fibrosis in children aged 1-<2yrs. The company will collaborate closely with payers to secure access for this new patient population shortly. P-III study evaluating Orkambi in 46 children aged 1 to <2yrs.

Labelling 40

Labelling 40

PharmaShots

APRIL 25, 2023

The product is now available to patients in 9 global markets, incl. the US for POMC, PCSK1, or LEPR deficiency obesity and/or BBS Ref: Rhythm | Image: Rhythm Related News:- Rhythm’s Imcivree (setmelanotide) Receives EC’s Approval for the Treatment of Bardet-Biedl Syndrome

40

40

pharmaphorum

JANUARY 20, 2022

This news will likely be welcomed by sufferers, as, currently, there is no cure for UC. Galapagos, based in Belgium, is responsible for the commercialisation of the product in Europe, while Gilead holds the rights outside of Europe, including in Japan, where it is co-marketed with Eisai.

98

98

European Pharmaceutical Review

SEPTEMBER 11, 2023

About the biosimilar development deal This agreement will help to expand access to biosimilar medicines , according to Samsung Bioepis. Adalimumab biosimilars shaping market, research states Last month, Sandoz announced it was going to seek regulatory approval for its aflibercept biosimilar in the US and EU in the coming months.

Biosimilars 78

Biosimilars 78

European Pharmaceutical Review

OCTOBER 14, 2022

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. New biosimilars allow more companies to invest additional funds in novel, pioneering treatments.

Biosimilars 83

Biosimilars 83

Pharmaceutical Technology

NOVEMBER 14, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients. Currently, the company is analysing Pepaxti’s market access options in the country.

52

52

Express Pharma

MARCH 23, 2023

Médecins Sans Frontières /Doctors without Borders (MSF) welcomed this as a significant step toward increasing access to the lifesaving TB drug. On the eve of World TB Day, the rejection of the patent for the salt form of bedaquiline by the Indian Patent Office is welcome news for people with drug-resistant TB in India.

96

96

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

European Pharmaceutical Review

OCTOBER 28, 2022

A new report , Addressing Europe’s Medicine Exodus by Teva called on legislators to ensure a safer, more secure supply of essential medicines for EU patients, by cutting reliance on low-cost markets. Newer markets often offer high state subsidies, lower labour costs and energy prices at a fraction of Western Europe’s.

Diabetes 89

Diabetes Pharmaceutical Companies Pharmaceutical Companies 89

pharmaphorum

SEPTEMBER 30, 2022

” (1/2) BREAKING NEWS: @US_FDA approved AMX0035, a new treatment that has been shown to slow progression of #ALS and extend life. ” In both the US and Canada, staying on the market will depend on the outcome of the 600-patient PHOENIX study in two years. . Bad news for Biohaven. pic.twitter.com/Kck0tp1nSJ.

Specialty Pharmacies 98

Specialty Pharmacies Labelling Hospitals Drug Development 98

European Pharmaceutical Review

AUGUST 26, 2022

Moderna pledged in October 2020 that, to enable equitable global access to vaccines, it would note enforce its COVID-19 related patents while the pandemic continued. As of March 2022, Moderna says that the situation has changed, and with vaccine supply no longer a barrier to access in many parts of the world, it is now updating the pledge.

Vaccines 92

Vaccines Immunity Immunization 92

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

96

96

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

94

94

pharmaphorum

JULY 11, 2022

“Improving access to new therapies is crucial to enable clinicians to select the most appropriate therapy for each individual patient, so this is welcomed news for those living with PsA,” she said. The post NICE makes J&J’s Tremfya more accessible in England and Wales appeared first on.

52

52

pharmaphorum

FEBRUARY 8, 2021

In the third part of this series taking stock of t he 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third VPAS objective that relates to the economy and innovation. That said, there is good news on the R&D front. Encouragement of R&D. But not by much; it went from £377.3

104

104

pharmaphorum

FEBRUARY 24, 2022

Following a period of restricted access, the once-a-day capsule will now be recommended for routine use in the NHS. . Initially, NICE cleared niraparib to be made available through the Cancer Drugs Fund (CDF) – a programme designed to increase the speed of drugs to market within spending margins – in 2021.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

JUNE 9, 2021

Our ambitious growth strategy plays a crucial role in helping us to achieve our mission of improving access and empowering healthcare professionals and patients with the knowledge needed to save lives. The post Welcoming analytics-driven digital marketing agency closerlook to the Fishawack Health pack appeared first on.

Communication 72

Communication 72

pharmaphorum

JANUARY 12, 2022

Biogen and partner Eisai had been hoping for good news from the review of Aduhelm (aducanumab) by the Centre for Medicare and Medicaid Services (CMS), but the draft decision means broad coverage of the drug will have to wait for the outcome of ongoing studies before it can hope for broader coverage.

52

52

pharmaphorum

JULY 20, 2022

It might not have been much in the way of news coverage, but it was picked up in a few places. That savings come from patents expiring is not news, but it does highlight how there can be a major impact on spend. Freeing up spend for fast access to innovative medicines. billion in three years. Genericisation. No mention of VPAS.

Hospitals 52

Hospitals 52

pharmaphorum

APRIL 26, 2022

The news is a timely boost for Paris, France-based Valneva, which is facing uncertain prospects for its COVID-19 vaccine after the EU regulator requested more data on the latecomer candidate this week despite a UK approval earlier in April. The post Readout sets up phase 3 for Valneva/Pfizer’s Lyme disease jab appeared first on.

Vaccines 67

Vaccines 67

European Pharmaceutical Review

APRIL 11, 2024

The centre is helping to set out a vision for a more sustainable future for the sector, by working with businesses across the industry and giving them access to state-of-the-art facilities and academic knowledge. This allows a more detailed understanding of exactly how different variables affect the outcomes.

Pharmaceutical Manufacturing 98

Pharmaceutical Manufacturing 98

Pharmaceutical Technology

SEPTEMBER 2, 2022

Multiple myeloma (MM) therapeutics comprise a multi-billion dollar market, among the most valuable in oncology. Last month, the European Medicines Agency's (EMA) approval of Johnson & Johnson’s (J&J) anti-CD3/BCMA bispecific antibody Tecvayli (teclistamab) marked the fourth anti-BCMA biologic to enter the R/R MM market.

Labelling 59

Labelling 59

pharmaphorum

OCTOBER 12, 2021

The approval brought the drug into direct competition with Ongentys (opicapone) from Neurocrine Biosciences, which was approved for the same use last year, and having access to Supernus’ sales force will help in the marketing battle between the two drugs. per share subject to Gocovri meeting sales targets.

97

97

pharmaphorum

MARCH 4, 2022

New survey data from Press Ganey suggests that pharma may be able to get an edge by integrating physician directories into brand websites. But in 2022, with digital communication ubiquitous, pharma companies are finding another option: market to consumers, then help them select a physician.

Communication 98

Communication Vaccines 98

pharmaphorum

JULY 27, 2022

Despite the UK’s potential as an international life sciences leader, it lags many competitors in a number of key metrics, including access to new medicines and global share of clinical trial recruitment. Access to medicines. Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI.

Documentation 98

Documentation 98

pharmaphorum

AUGUST 7, 2020

Find out more in our roundup of the biggest R&D, market access and digital stories from the past week. The post Coronavirus pharma news roundup – 07/08/20 appeared first on. Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales.

Nursing Homes 104

Nursing Homes Vaccines Immunity Immunization 104

pharmaphorum

DECEMBER 10, 2020

The European Medicines Agency (EMA) says it suffered a cyberattack, with documents relating to a Pfizer and BioNTech’s COVID-19 vaccine accessed. Shortly after however BioNTech confirmed that documents submitted as part of its marketing application for coronavirus vaccine BNT-162b had been accessed by the hackers.

Vaccines 109

Vaccines Documentation 109

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. Government partnerships are crucial to accessibility.

Packaging 52

Packaging Compounding Labelling 52

pharmaphorum

AUGUST 17, 2022

The indicators did not bring universal good news , but Leela Barham argues we need to consider whether the indicators are measuring what matters most if we are to understand more about the health of the UK life sciences industry and, most importantly, what it means for patients. This can be taken as an attempt to be a little more systematic.

57

57